Press Resease

Intravenous Immunoglobulin Market by Component (IgG, IgA, IgM, IgE, and IgD), by Application (Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Idiopathic Thrombocytopenic Purpura, Hypogammaglobulinemia, Multifocal Motor Neuropathy, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, and Others), and by End-User (Hospitals, Clinics, and Homecare Settings): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 30-Jul-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2934 Status : Published

Global intravenous immunoglobulin market expected to generate around USD 16.42 billion by 2025, at a CAGR of around 7.6% between 2019 and 2025. Immunoglobulins are glycoproteins that are often produced in the blood plasma, which respond to antigens present in the body.

Description

The report covers a forecast and an analysis of the global intravenous immunoglobulin market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes the drivers and restraints of the intravenous immunoglobulin market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in intravenous immunoglobulin market on a global level.

In order to give the users of this report a comprehensive view of the intravenous immunoglobulin market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations &joint ventures, research and development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the intravenous immunoglobulin market by component, application, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some major players of the global intravenous immunoglobulin market are LFB Biotechnologies, Biotest, Octapharma, Grifols, CSL Behring, China Biologics Products, Kedrion Biopharma, BDI Pharma, Shire, and CSL Behring.

This report segments the global intravenous immunoglobulin market into:

Global Intravenous Immunoglobulin Market: Component Analysis

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

Global Intravenous Immunoglobulin Market: Application Analysis

  • Immunodeficiency Diseases
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Idiopathic Thrombocytopenic Purpura
  • Hypogammaglobulinemia
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain-Barre Syndrome
  • Others

Global Intravenous Immunoglobulin Market: End-User Analysis

  • Hospitals
  • Clinics
  • Homecare Settings

Global Intravenous Immunoglobulin Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global intravenous immunoglobulin market, 2016-2025 (USD Billion)
    • 2.2. Global intravenous immunoglobulin market: Snapshot
  •  
  • Chapter 3. Intravenous Immunoglobulin Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Intravenous Immunoglobulin Market drivers: impact analysis
      • 3.2.2. The high rate of nutritional deficiency globally
      • 3.2.3. The increasing number of hemophilic patients
      • 3.2.4. Improved technology for high production of intravenous immunoglobulin and enhancement of purification techniques
      • 3.2.5. Government initiatives for improving healthcare facilities in developing countries
      • 3.2.6. Growing R&D in intravenous immunoglobulin medications
    • 3.3. Market Restraints
      • 3.3.1. Global Intravenous Immunoglobulin Market restraints: Impact analysis
      • 3.3.2. The high cost of treatment
      • 3.3.3. Lack of awareness
      • 3.3.4. Potential side-effects of intravenous immunoglobulin medicines
    • 3.4. Opportunities
      • 3.4.1. Evolving market
      • 3.4.2. Advanced technology
      • 3.4.3. Growing immunodeficiency
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by component
      • 3.6.2. Market attractiveness analysis, by application
      • 3.6.3. Market attractiveness analysis, by End-user
      • 3.6.4. Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Intravenous Immunoglobulin Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global intravenous immunoglobulin market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New instruments launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Intravenous Immunoglobulin Market - Component Analysis
    • 5.1. Global intravenous immunoglobulin market: component overview
      • 5.1.1. Global intravenous immunoglobulin market share, by component, 2018 and 2025
    • 5.2. IgG
      • 5.2.1. Global intravenous immunoglobulin market for IgG, 2016-2025 (USD Billion)
    • 5.3. IgA
      • 5.3.1. Global intravenous immunoglobulin market for IgA, 2016-2025 (USD Billion)
    • 5.4. IgM
      • 5.4.1. Global intravenous immunoglobulin market for IgM, 2016-2025 (USD Billion)
    • 5.5. IgE
      • 5.5.1. Global intravenous immunoglobulin market for IgE, 2016-2025 (USD Billion)
    • 5.6. IgD
      • 5.6.1. Global intravenous immunoglobulin market for IgD, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Intravenous Immunoglobulin Market - Application Analysis
    • 6.1. Global intravenous immunoglobulin market: application overview
      • 6.1.1. Global intravenous immunoglobulin market share, by application, 2018 and 2025
    • 6.2. Immunodeficiency Diseases
      • 6.2.1. Intravenous immunoglobulin market for immunodeficiency disease, 2016-2025 (USD Billion)
    • 6.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 6.3.1. Global intravenous immunoglobulin market for chronic inflammatory demyelinating polyneuropathy, 2016-2025 (USD Billion)
    • 6.4. Idiopathic Thrombocytopenic Purpura
      • 6.4.1. Global intravenous immunoglobulin market for idiopathic thrombocytopenic purpura, 2016-2025 (USD Billion)
    • 6.5. Multifocal Motor Neuropathy
      • 6.5.1. Global intravenous immunoglobulin market for multifocal motor neuropathy, 2016-2025 (USD Billion)
    • 6.6. Hypogammaglobulinemia
      • 6.6.1. Global intravenous immunoglobulin market for hypogammaglobulinemia, 2016-2025 (USD Billion)
    • 6.7. Myasthenia Gravis
      • 6.7.1. Global intravenous immunoglobulin market for myasthenia, 2016-2025 (USD Billion)
    • 6.8. Inflammatory Myopathies
      • 6.8.1. Global intravenous immunoglobulin market for inflammatory myopathies, 2016-2025 (USD Billion)
    • 6.9. Specific Antibody Deficiency
      • 6.9.1. Global intravenous immunoglobulin market for specific antibody deficiency, 2016-2025 (USD Billion)
    • 6.10. Guillain-Barre syndrome
      • 6.10.1. Global intravenous immunoglobulin market for Guillain-Barre syndrome, 2016-2025 (USD Billion)
    • 6.11. Others
    • 6.11.1. Global intravenous immunoglobulin market for others, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Intravenous Immunoglobulin Market -End-user Analysis
    • 7.1. Global intravenous immunoglobulin market: End-user overview
      • 7.1.1. Global intravenous immunoglobulin market share, by End-user, 2018 and 2025
    • 7.2. Hospitals
      • 7.2.1. Global intravenous immunoglobulin market for hospitals, 2016-2025 (USD Billion)
    • 7.3. Clinics
      • 7.3.1. Global intravenous immunoglobulin market for clinics, 2016-2025 (USD Billion)
    • 7.4. Homecare Setting
      • 7.4.1. Global intravenous immunoglobulin market for homecare setting, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Global Intravenous Immunoglobulin Market - Regional Analysis
    • 8.1. Global intravenous immunoglobulin market: regional overview
      • 8.1.1. Global intravenous immunoglobulin market share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America intravenous immunoglobulin market, 2016-2025 (USD Billion)
      • 8.2.2. North America intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
      • 8.2.3. North America intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
      • 8.2.4. North America intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S. intravenous immunoglobulin market, by component, 2016-2025 (USD Billion)
        • 8.2.5.2. The U.S. intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.2.5.3. The U.S. intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.2.6. Canada
        • 8.2.6.1. Canada intravenous immunoglobulin market, by component, 2016-2025 (USD Billion)
        • 8.2.6.2. Canada intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.2.6.3. Canada intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe intravenous immunoglobulin market revenue, 2016-2025 (USD Billion)
      • 8.3.2. Europe intravenous immunoglobulin market revenue, by component, 2016-2025( USD Billion)
      • 8.3.3. Europe intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
      • 8.3.4. Europe intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.3.5. U.K.
        • 8.3.5.1. U.K. intravenous immunoglobulin market, by component, 2016-2025 (USD Billion)
        • 8.3.5.2. U.K. intravenous immunoglobulin market, by application, 2016-2025 (USD Billion)
        • 8.3.5.3. U.K. intravenous immunoglobulin market, by End-user, 2016-2025 (USD Billion)
      • 8.3.6. Germany
        • 8.3.6.1. Germany intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
        • 8.3.6.2. Germany intravenous immunoglobulin market, by application, 2016-2025 (USD Billion)
        • 8.3.6.3. Germany intravenous immunoglobulin market, by End-user ,2016-2025 (USD Billion)
      • 8.3.7. France
        • 8.3.7.1. France intravenous immunoglobulin market revenue, by component, 2016-20259USD Billion)
        • 8.3.7.2. France intravenous immunoglobulin market, by application, 2016-2025 (USD Billion)
        • 8.3.7.3. France intravenous immunoglobulin market, by End-user,2016-2025 (USD Billion)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe intravenous immunoglobulin market revenue, by component, 2016-2025 USD Billion)
        • 8.3.8.2. Rest of Europe intravenous immunoglobulin market, by application, 2016-2025 (USD Billion)
        • 8.3.8.3. Rest of Europe intravenous immunoglobulin market, by End-user, 2016-2025 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific intravenous immunoglobulin market, 2016-2025 (USD Billion)
      • 8.4.2. Asia Pacific intravenous immunoglobulin market revenue, by component, 2016-20259 (USD Billion)
      • 8.4.3. Asia Pacific intravenous immunoglobulin market revenue, by application, 2016-20259 (USD Billion)
      • 8.4.4. Asia Pacific intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.4.5. China
        • 8.4.5.1. China intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
        • 8.4.5.2. China intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.4.5.3. China intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.4.6. Japan
        • 8.4.6.1. Japan intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
        • 8.4.6.2. Japan intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.4.6.3. Japan intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.4.7. India
        • 8.4.7.1. India intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
        • 8.4.7.2. India intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.4.7.3. India intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
        • 8.4.8.2. Rest of Asia Pacific intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.4.8.3. Rest of Asia Pacific intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America intravenous immunoglobulin market, 2016-2025 (USD Billion)
      • 8.5.2. Latin America intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
      • 8.5.3. Latin America intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
      • 8.5.4. Latin America intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
        • 8.5.5.2. Brazil intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.5.5.3. Brazil intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
        • 8.5.6.2. Rest of Latin America intravenous immunoglobulin market revenue, by application, 2016-2025 (USD Billion)
        • 8.5.6.3. Rest of Latin America intravenous immunoglobulin market revenue, by End-user, 2016-2025 (USD Billion)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa intravenous immunoglobulin market, 2016-2025 (USD Billion)
      • 8.6.2. The Middle East and Africa intravenous immunoglobulin market revenue, by component, 2016-2025 (USD Billion)
      • 8.6.3. The Middle East and Africa intravenous immunoglobulin market, by application, 2016-2025 (USD Billion)
      • 8.6.4. The Middle East and Africa intravenous immunoglobulin market, by End-user, 2016-2025 (USD Billion)
  •  
  • Chapter 9. Company Profile
    • 9.1. LFB Biotechnologies
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Biotest AG
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Octapharma AG
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Grifols S.A.
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. CSL Behring
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Developments
    • 9.6. China Biologics Products
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Developments
    • 9.7. Kedrion Biopharma
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Developments
    • 9.8. BDI Pharma
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Developments
    • 9.9. Shire
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Developments
    • 9.10. CSL Behring
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Product Portfolio
      • 9.10.4. Business Strategy
      • 9.10.5. Recent Developments

Methodology

Free Analysis

Intravenous immunoglobulin is a blood product that is prepared from the serum of about 1,000 to 10,000 donors per batch. This type of treatment is used for treating patients with antibody deficiencies. For this purpose, IVIG is used at a replacement dose of 200–400 mg/kg body weight, which is given approximately for about 3-weeks. Immunoglobulins are glycoproteins that are often produced in the blood plasma, which respond to antigens present in the body. They are obtained from the blood via fractionation and are purified for various applications.

Significant rise in the global geriatric population, increase in the number of hemophilic patients, improved technology for high production of intravenous immunoglobulin, and enhancements in the purification techniques are the major factors fueling the global intravenous immunoglobulin market. Moreover, the increasing government initiatives for treating hemophilic patients and rising cases of CIDP and hypogammaglobulinemia are also fueling the market. However, strict government regulations pertaining to intravenous immunoglobulin usage due to its harmful side-effects may hinder the market globally. Alternatively, growing per capita disposable income of people across the world, rising active role of distributors, developing advanced healthcare facilities, and increasing awareness among people are some other factors further fueling the intravenous immunoglobulin market globally.

The intravenous immunoglobulin market is divided on the basis of component, application, and end-user. Based on component, the intravenous immunoglobulin market includes IgM, IgA, IgE, IgD, and IgG. By application, the market includes immunodeficiency diseases, Guillain-Barre syndrome, hypogammaglobulinemia, multifocal motor neuropathy, CIDP (chronic inflammatory demyelinating polyneuropathy), thrombocytopenic purpura, specific antibody deficiency, inflammatory myopathies, myasthenia gravis, and others. Based on end-user, the market for intravenous immunoglobulin comprises hospitals, homecare settings, and clinics.

North America is likely to dominate the global intravenous immunoglobulin market, owing to the early introduction of highly developed techniques, increasing hemophilic patients due to changing lifestyle patterns, and rising disposable income of the regional population. The Asia Pacific region is anticipated to show a high rate of growth in the upcoming years, owing to the rising investments and funding by private organizations, active participation of online and offline distribution networks, increasing population, growing establishments of health clinics and hospitals in India and China, and rising number of patients suffering from hemophilic diseases.

Some major players of the global intravenous immunoglobulin market are LFB Biotechnologies, Biotest, Octapharma, Grifols, CSL Behring, China Biologics Products, Kedrion Biopharma, BDI Pharma, Shire, and CSL Behring.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com